GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clinuvel Pharmaceuticals Ltd (FRA:UR9) » Definitions » 3-Month Share Buyback Ratio

Clinuvel Pharmaceuticals (FRA:UR9) 3-Month Share Buyback Ratio : 0.00% (As of Dec. 2024 )


View and export this data going back to 2004. Start your Free Trial

What is Clinuvel Pharmaceuticals 3-Month Share Buyback Ratio?

3-Month Share Buyback Ratio only apply to companies whose reporting frequency is 3 months.


Clinuvel Pharmaceuticals Business Description

Traded in Other Exchanges
Address
535 Bourke Street, Level 22, Melbourne, VIC, AUS, 3000
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.